HD-OPM Archive
Topics › Supplements & vitamins

Vitamin K2 (MK-7) slowed coronary calcium progression in a 2-year randomized trial

Louis Nervegna · Sep 08, 2026 · ♥ 12 reactions · 4 comments · original Facebook post
Supplements & vitaminsPlaque, CAC & CT angiography
AI summary & key facts

A shared summary of a randomized trial in 180 adults with symptomatic coronary artery disease and existing calcium found that 360 mcg/day MK-7 slowed CAC progression versus placebo over two years. It did not remove existing calcium, CAC is a surrogate marker, and the trial was not designed to show fewer heart attacks.

#vitaminkHD #cacHD

Research cited

Vitamin K2 is often discussed in cardiovascular health because vitamin K is required to activate matrix Gla protein, one of the proteins involved in regulating vascular calcification. A new randomized trial provides direct human evidence that this pathway may have a measurable effect on coronary calcium progression.

Researchers randomized 180 adults with symptomatic coronary artery disease and existing coronary calcium to 360 µg/day of menaquinone-7 (MK-7) or placebo for two years. Coronary calcium increased in both groups, but progression was significantly slower with MK-7. Median CAC score increased by 69 Agatston units with placebo versus 49 with MK-7. Using those median changes descriptively, that is about a 29% smaller increase in the MK-7 group.

The important distinction is that vitamin K2 did not remove existing calcium. The signal was slower progression over time.

And coronary calcium is still a surrogate marker. This trial was not designed to show fewer heart attacks, strokes, or deaths, and the authors specifically note that the clinical meaning of the slower calcification remains uncertain. A larger outcomes trial would be needed before MK-7 could be considered established cardiovascular therapy.

So the finding is promising. Two years of MK-7 altered the trajectory of coronary calcification in people who already had coronary artery disease.

Reference:
Vossen LM, et al. JAMA Cardiol. 2026;11(8):719-726. PMID: 42268593. DOI: 10.1001/jamacardio.2026.1279.

May be an image of xray and text
← newer: High-dose vitamin B6 can cause sensory neuropathy despite beolder: How insulin signals cells to take up glucose (video) →